KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Adaptive Biotechnologies (ADPT) Gross Margin (2018 - 2025)

Historic Gross Margin for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to 75.02%.

  • Adaptive Biotechnologies' Gross Margin rose 192800.0% to 75.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.73%, marking a year-over-year increase of 117300.0%. This contributed to the annual value of 52.64% for FY2024, which is 46600.0% up from last year.
  • Adaptive Biotechnologies' Gross Margin amounted to 75.02% in Q3 2025, which was up 192800.0% from 59.96% recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Gross Margin peaked at 75.02% during Q3 2025, and registered a low of 210.03% during Q2 2023.
  • In the last 5 years, Adaptive Biotechnologies' Gross Margin had a median value of 46.7% in 2024 and averaged 35.33%.
  • Its Gross Margin has fluctuated over the past 5 years, first crashed by -2544100bps in 2023, then soared by 2629900bps in 2024.
  • Adaptive Biotechnologies' Gross Margin (Quarter) stood at 29.62% in 2021, then skyrocketed by 93bps to 57.03% in 2022, then decreased by -9bps to 52.15% in 2023, then grew by 5bps to 54.54% in 2024, then soared by 38bps to 75.02% in 2025.
  • Its last three reported values are 75.02% in Q3 2025, 59.96% for Q2 2025, and 56.05% during Q1 2025.